Sciwind Biosciences Secures Global Exclusive Rights to Sanofi’s GIP Receptor Agonist for Metabolic Diseases

HANGZHOU, China and SAN FRANCISCO, U.S., November 30, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., a clinical-stage biotechnology company focused on research and development of innovative therapies for chronic metabolic diseases, today announced that it has entered into a global exclusive license agreement with Sanofi. Under the agreement, Sciwind has been granted global development and commercialization rights to Sanofi's long-acting glucose-dependent insulinotropic peptide (GIP) receptor agonist program, which is currently in preclinical development.

Under the terms of the agreement, Sanofi grants Sciwind the global exclusive rights to develop, manufacture, and commercialize its GIP receptor agonist program for all relevant indications. The GIP receptor agonist has the potential to further enhance the efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obesity and diabetes, as well as improve their overall safety and tolerability. Sciwind plans to rapidly advance the development of a combination therapy involving the GIP receptor agonist and XW003, its GLP-1 candidate currently in Phase II clinical trials for the treatment of diabetes, obesity, and NASH.

Dr. Hai Pan, Founder and CEO of Sciwind, stated: "We are very pleased to reach this licensing agreement with Sanofi, which will further advance our goal of providing the best therapeutic solutions for patients with metabolic diseases worldwide. We look forward to initiating clinical studies on the combination therapy of Sanofi's long-acting GIP receptor agonist and Sciwind’s GLP-1 receptor agonist as soon as possible, aiming to provide Chinese and global patients suffering from metabolic diseases with more effective and better-tolerated drug combination therapies."